The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10434 malaria professionals are enjoying the free benefits of MalariaWorld today

PCR

PCR correction strategies for malaria drug trials: updates and clarifications

January 20, 2020 - 15:01 -- Open Access
Author(s): 
Felger I, Snounou G, Hastings I, Moehrle JJ, Beck HP
Reference: 
Lancet Infect Dis. 2020 Jan; 20(1):e20-e25

Malaria drug trials conducted in endemic areas face a major challenge in their analysis because it is difficult to establish whether parasitaemia in blood samples collected after treatment indicate drug failure or a new infection acquired after treatment. It is therefore vital to reliably distinguish drug failures from new infections in order to obtain accurate estimates of drug failure rates.

Multiplex malaria antigen detection by bead-based assay and molecular confirmation by PCR shows no evidence of Pfhrp2 and Pfhrp3 deletion in Haiti

December 3, 2019 - 15:31 -- Open Access
Author(s): 
Camelia Herman, Curtis S. Huber, Sophie Jones, Laura Steinhardt, Mateusz M. Plucinski, Jean F. Lemoine, Michelle Chang, John W. Barnwell, Venkatachalam Udhayakumar and Eric Rogier
Reference: 
Malaria Journal 2019 18:380, 27 November 2019

The Plasmodium falciparum parasite is the only human malaria that produces the histidine-rich protein 2 and 3 (HRP2/3) antigens. Currently, HRP2/3 are widely used in malaria rapid diagnostic tests (RDTs), but several global reports have recently emerged showing genetic deletion of one or both of these antigens in parasites. Deletion of these antigens could pose a major concern for P. falciparum diagnosis in Haiti which currently uses RDTs based solely on the detection of the HRP2/3 antigens.

Medical Condition: 
Subscribe to RSS - PCR